Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001435
Filing Date
2024-08-14
Accepted
2024-08-14 16:05:46
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q seel-20240630x10q.htm   iXBRL 10-Q 2163525
2 EX-31.1 seel-20240630xex31d1.htm EX-31.1 14649
3 EX-31.2 seel-20240630xex31d2.htm EX-31.2 15223
4 EX-32.1 seel-20240630xex32d1.htm EX-32.1 6421
5 EX-32.2 seel-20240630xex32d2.htm EX-32.2 6369
  Complete submission text file 0001410578-24-001435.txt   8775893

Data Files

Seq Description Document Type Size
6 EX-101.SCH seel-20240630.xsd EX-101.SCH 62512
7 EX-101.CAL seel-20240630_cal.xml EX-101.CAL 37556
8 EX-101.DEF seel-20240630_def.xml EX-101.DEF 259643
9 EX-101.LAB seel-20240630_lab.xml EX-101.LAB 513502
10 EX-101.PRE seel-20240630_pre.xml EX-101.PRE 417376
72 EXTRACTED XBRL INSTANCE DOCUMENT seel-20240630x10q_htm.xml XML 1398069
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

EIN.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22245 | Film No.: 241207530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)